Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates

Oriel Spierer, Jyoti Dugar, Darlene Miller, Terrence O'Brien

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To compare the in vitro activity of topical amphotericin B (AMB), natamycin, voriconazole, and fluconazole against human corneal isolates of Candida sp. for guidance in the treatment of Candida keratitis. Methods: Sixty-eight Candida isolates (37 albicans and 31 nonalbicans isolates) recovered from corneal scrapings submitted to rule out microbial keratitis, during the years 2005 to 2011, at the Bascom Palmer Eye Institute, were examined in this study. Corneal isolates were cultured on fungal agars for 48 hours. Each yeast isolate was dispensed into 4 microtiter wells, each containing 100 mL of commercial (natamycin 5%) or compounded (AMB 0.15%, voriconazole 1%, and fluconazole 0.2%) antifungal medications. A comparison of growth patterns was conducted. Results: One hundred percent of the samples showed growth inhibition after treatment exposure with AMB or natamycin. The isolates treated with voriconazole demonstrated an 85% inhibition rate overall, with the Candida albicans samples showing a 77% inhibition rate and the non-albicans sp. a 93% inhibition rate. In the fluconazole group, there was only a 19.6% inhibition rate noted, with a 7.7% inhibition rate observed in the C. albicans group versus a 30% inhibition rate in the non-albicans group. Conclusions: AMB 0.2% and natamycin 5% have equal effectiveness and full inhibition against Candida keratitis isolates. Fluconazole 0.2% is not the drug of choice in both C. albicans and non-albicans keratitis. Voriconazole 1% may need a stronger concentration for higher effectiveness, but potentially may be helpful as a second agent in the treatment of Candida keratitis.

Original languageEnglish (US)
Pages (from-to)576-579
Number of pages4
JournalCornea
Volume34
Issue number5
DOIs
StatePublished - Mar 2 2015

Fingerprint

Natamycin
Keratitis
Candida albicans
Candida
Fluconazole
Amphotericin B
Growth
Agar
Yeasts
Voriconazole
Pharmaceutical Preparations

Keywords

  • amphotericin B
  • Candida albicans
  • fluconazole
  • infectious keratitis
  • natamycin
  • non-albicans Candida
  • voriconazole

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates. / Spierer, Oriel; Dugar, Jyoti; Miller, Darlene; O'Brien, Terrence.

In: Cornea, Vol. 34, No. 5, 02.03.2015, p. 576-579.

Research output: Contribution to journalArticle

@article{20e57f53e557448bb1e2d201cad94f3e,
title = "Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates",
abstract = "Purpose: To compare the in vitro activity of topical amphotericin B (AMB), natamycin, voriconazole, and fluconazole against human corneal isolates of Candida sp. for guidance in the treatment of Candida keratitis. Methods: Sixty-eight Candida isolates (37 albicans and 31 nonalbicans isolates) recovered from corneal scrapings submitted to rule out microbial keratitis, during the years 2005 to 2011, at the Bascom Palmer Eye Institute, were examined in this study. Corneal isolates were cultured on fungal agars for 48 hours. Each yeast isolate was dispensed into 4 microtiter wells, each containing 100 mL of commercial (natamycin 5{\%}) or compounded (AMB 0.15{\%}, voriconazole 1{\%}, and fluconazole 0.2{\%}) antifungal medications. A comparison of growth patterns was conducted. Results: One hundred percent of the samples showed growth inhibition after treatment exposure with AMB or natamycin. The isolates treated with voriconazole demonstrated an 85{\%} inhibition rate overall, with the Candida albicans samples showing a 77{\%} inhibition rate and the non-albicans sp. a 93{\%} inhibition rate. In the fluconazole group, there was only a 19.6{\%} inhibition rate noted, with a 7.7{\%} inhibition rate observed in the C. albicans group versus a 30{\%} inhibition rate in the non-albicans group. Conclusions: AMB 0.2{\%} and natamycin 5{\%} have equal effectiveness and full inhibition against Candida keratitis isolates. Fluconazole 0.2{\%} is not the drug of choice in both C. albicans and non-albicans keratitis. Voriconazole 1{\%} may need a stronger concentration for higher effectiveness, but potentially may be helpful as a second agent in the treatment of Candida keratitis.",
keywords = "amphotericin B, Candida albicans, fluconazole, infectious keratitis, natamycin, non-albicans Candida, voriconazole",
author = "Oriel Spierer and Jyoti Dugar and Darlene Miller and Terrence O'Brien",
year = "2015",
month = "3",
day = "2",
doi = "10.1097/ICO.0000000000000380",
language = "English (US)",
volume = "34",
pages = "576--579",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates

AU - Spierer, Oriel

AU - Dugar, Jyoti

AU - Miller, Darlene

AU - O'Brien, Terrence

PY - 2015/3/2

Y1 - 2015/3/2

N2 - Purpose: To compare the in vitro activity of topical amphotericin B (AMB), natamycin, voriconazole, and fluconazole against human corneal isolates of Candida sp. for guidance in the treatment of Candida keratitis. Methods: Sixty-eight Candida isolates (37 albicans and 31 nonalbicans isolates) recovered from corneal scrapings submitted to rule out microbial keratitis, during the years 2005 to 2011, at the Bascom Palmer Eye Institute, were examined in this study. Corneal isolates were cultured on fungal agars for 48 hours. Each yeast isolate was dispensed into 4 microtiter wells, each containing 100 mL of commercial (natamycin 5%) or compounded (AMB 0.15%, voriconazole 1%, and fluconazole 0.2%) antifungal medications. A comparison of growth patterns was conducted. Results: One hundred percent of the samples showed growth inhibition after treatment exposure with AMB or natamycin. The isolates treated with voriconazole demonstrated an 85% inhibition rate overall, with the Candida albicans samples showing a 77% inhibition rate and the non-albicans sp. a 93% inhibition rate. In the fluconazole group, there was only a 19.6% inhibition rate noted, with a 7.7% inhibition rate observed in the C. albicans group versus a 30% inhibition rate in the non-albicans group. Conclusions: AMB 0.2% and natamycin 5% have equal effectiveness and full inhibition against Candida keratitis isolates. Fluconazole 0.2% is not the drug of choice in both C. albicans and non-albicans keratitis. Voriconazole 1% may need a stronger concentration for higher effectiveness, but potentially may be helpful as a second agent in the treatment of Candida keratitis.

AB - Purpose: To compare the in vitro activity of topical amphotericin B (AMB), natamycin, voriconazole, and fluconazole against human corneal isolates of Candida sp. for guidance in the treatment of Candida keratitis. Methods: Sixty-eight Candida isolates (37 albicans and 31 nonalbicans isolates) recovered from corneal scrapings submitted to rule out microbial keratitis, during the years 2005 to 2011, at the Bascom Palmer Eye Institute, were examined in this study. Corneal isolates were cultured on fungal agars for 48 hours. Each yeast isolate was dispensed into 4 microtiter wells, each containing 100 mL of commercial (natamycin 5%) or compounded (AMB 0.15%, voriconazole 1%, and fluconazole 0.2%) antifungal medications. A comparison of growth patterns was conducted. Results: One hundred percent of the samples showed growth inhibition after treatment exposure with AMB or natamycin. The isolates treated with voriconazole demonstrated an 85% inhibition rate overall, with the Candida albicans samples showing a 77% inhibition rate and the non-albicans sp. a 93% inhibition rate. In the fluconazole group, there was only a 19.6% inhibition rate noted, with a 7.7% inhibition rate observed in the C. albicans group versus a 30% inhibition rate in the non-albicans group. Conclusions: AMB 0.2% and natamycin 5% have equal effectiveness and full inhibition against Candida keratitis isolates. Fluconazole 0.2% is not the drug of choice in both C. albicans and non-albicans keratitis. Voriconazole 1% may need a stronger concentration for higher effectiveness, but potentially may be helpful as a second agent in the treatment of Candida keratitis.

KW - amphotericin B

KW - Candida albicans

KW - fluconazole

KW - infectious keratitis

KW - natamycin

KW - non-albicans Candida

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84928029318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928029318&partnerID=8YFLogxK

U2 - 10.1097/ICO.0000000000000380

DO - 10.1097/ICO.0000000000000380

M3 - Article

C2 - 25826327

AN - SCOPUS:84928029318

VL - 34

SP - 576

EP - 579

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 5

ER -